Innova Captab (BOM:544067) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Innova Captab Debt-to-Asset?

Innova Captab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Innova Captab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Innova Captab's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₹0 Mil.

Innova Captab Debt-to-Asset Historical Data

The historical data trend for Innova Captab's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innova Captab Debt-to-Asset Chart

Innova Captab Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

Get a 7-Day Free Trial

0.18

0.12

0.35

0.34

0.19

Innova Captab Quarterly Data
	Mar19	Mar20	Mar21	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial									-	0.19	-	0.18	-

Competitive Comparison of Innova Captab's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innova Captab's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innova Captab's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Innova Captab's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Innova Captab Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Innova Captab's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(345.84	+	2105.2)	/	13208.81
	=	0.19

Innova Captab's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0
	=	N/A

Innova Captab (BOM:544067) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Innova Captab Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Innova Captab's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Innova Captab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innova Captab Ltd (BOM:544067) » Definitions » Debt-to-Asset

Traded in Other Exchanges

INNOVACAP:India

Address

SCO No. 301, Sector 9, Second Floor, Panchkula, HR, IND, 134109

Website

https://www.innovacaptab.com

Innova Captab Ltd is an integrated pharmaceutical company in India and is engaged in research and development, manufacturing, drug distribution, and marketing and exports. Company business includes (i) a contract development and manufacturing organization ("CDMO") business providing manufacturing services to Indian pharmaceutical companies, (ii) a domestic branded generics business, and (iii) an international branded generics business.

Innova Captab Headlines

No Headlines